🔄 Watchlist Update: Arctic Bioscience (ABS.OL)

Patient enrollment completed – countdown to pivotal psoriasis data begins

Arctic Bioscience has completed its phase 2b HeROPA clinical trial for HRO350 in mild-to-moderate psoriasis. All 519 patients have now finished one full year of treatment.

Top-line results were initially planned for Q1 2025, but data cleaning and quality control are taking longer than expected. The company now expects to release results within 2–3 weeks.

This is a critical binary event that could significantly reprice the stock – as outlined in our earlier post:
📖 Arctic Bioscience – A High-Risk, High-Reward Bet on Psoriasis Treatment

We’ll continue monitoring closely as this binary biotech bet approaches a major catalyst.